Mesothelin-targeted CAR T-cell therapy shows early promise in patients with solid tumors

A chimeric antigen receptor (CAR) T-cell therapy that targets the protein mesothelin showed no evidence of major toxicity and had antitumor activity in patients with malignant pleural disease from mesothelioma, according to new results.